The data presented indicates that the use of a vector construct targeting PP2A, under the transcriptional control of the AFP enhancer fragment and the pgk promoter, is a practical and promising strategy to deliver HCC-specific gene therapy. This evidence concerns the gene PRKG1 and hepatocellular carcinoma.